ARX vs RYAN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ARX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARX and RYAN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARX and RYAN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital.

Full ARX guide

Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon). It sits between retail insurance brokers and carriers, operating two core engines: wholesale brokerage (led by RT Specialty, one of the largest E&S and binding-authority platforms in the US) and underwriting management, where its managing general underwriters (MGUs) hold delegated authority from carriers to underwrite niche risks in areas like energy, healthcare, construction, and enterprise risk. It does not take underwriting risk on its own balance sheet; it earns commissions and fees for placing and structuring hard-to-place specialty coverage.

Full RYAN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARX drivers: Growing the exchange network; The capital-light shift.
• RYAN drivers: E&S market tailwind; Delegated underwriting (MGU) mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. For RYAN, the biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARX if you believe its drivers more; RYAN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARX and RYAN guides.

ARX. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Accelerant only listed in July 2025, its trading and reporting history is short, and its large statutory net loss diverges from the adjusted EBITDA it emphasizes, so the two frames tell different stories. The valuation reflects rapid revenue and EBITDA growth rather than current bottom-line profit, meaning the figures matter most as a gauge of how much future growth is already priced in.

RYAN. Ryan Specialty grew Q1 2026 revenue about 15% to roughly $795 million and returned to a quarterly net profit, with adjusted EPS up about 20%. The trailing P/E near 54x looks steep and reflects growth expectations, while the forward multiple near 19x is far lower because analysts expect earnings to catch up. Management trimmed full-year organic growth guidance to mid-single digits and expects some margin decline as property rates soften.

Headline figures (approximate, July 2026): ARX shows exchange written premium (fy 2025) ~$4.19 billion, up ~35% year over year, revenue (fy 2025 / q1 2026) ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%), adjusted ebitda ~$282 million FY 2025; ~$66 million in Q1 2026 (up ~69%), net income (fy 2025) ~$1.35 billion loss, almost all from a ~$1.38 billion non-cash IPO item; RYAN shows revenue (ttm) ~$3.0B, q1 2026 revenue ~$795M (up ~15% YoY), organic growth (q1 2026) ~11.8%, adjusted ebitda margin ~29%.

ARX and RYAN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARX and RYAN exposure against your real portfolio. It is not an investment adviser.